Literature DB >> 29616457

Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies.

Ahmad Baraka1, Marwa Zakaria2.   

Abstract

Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study. Estimation of presepsin, procalcitonin (PCT), and C-reactive protein (CRP) during episode of FN in addition to absolute neutrophils count (ANC) and blood culture was performed for all the participants. Presepsin levels were higher in the patients than in control with a higher increments in the positive blood cultures than the sterile cases. Presepsin concentration was significantly higher in bacteremia than clinically proved infection and fever of unknown origin. A statistically significant positive correlation between presepsin and CRP plus PCT levels but negative correlation with ANC were observed in the patients subgroups. Presepsin is a useful marker for detection of bacteremia with sensitivity and specificity (100 and 85.7%). This finding supported that presepsin was superior to PCT and CRP in identifying bacterial infection in FN.

Entities:  

Keywords:  CRP; Febrile neutropenia; Hematological malignancies (HEM); PCT; Presepsin

Mesh:

Substances:

Year:  2018        PMID: 29616457     DOI: 10.1007/s12185-018-2447-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.

Authors:  Tatsuyori Shozushima; Gaku Takahashi; Naoya Matsumoto; Masahiro Kojika; Yoshikazu Okamura; Shigeatsu Endo
Journal:  J Infect Chemother       Date:  2011-05-12       Impact factor: 2.211

Review 2.  Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification.

Authors:  Claudio Viscoli; Oliviero Varnier; Marco Machetti
Journal:  Clin Infect Dis       Date:  2005-04-01       Impact factor: 9.079

3.  Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study.

Authors:  Shigeatsu Endo; Yasushi Suzuki; Gaku Takahashi; Tatsuyori Shozushima; Hiroyasu Ishikura; Akira Murai; Takeshi Nishida; Yuhei Irie; Masanao Miura; Hironobu Iguchi; Yasuo Fukui; Kimiaki Tanaka; Tsuyoshi Nojima; Yoshikazu Okamura
Journal:  J Infect Chemother       Date:  2012-06-13       Impact factor: 2.211

4.  Increasing Antimicrobial Resistance Monitored in Surveillance Analysis of Blood Stream Infections in Febrile Neutropenic Pediatric Oncology Patients.

Authors:  Hadir A El-Mahallawy; Safaa Shawky Hassan; Mohamed El-Wakil; Manar M Moneer; Lobna Shalaby
Journal:  Asian Pac J Cancer Prev       Date:  2015

5.  Value of measurement of C-reactive protein in febrile patients with hematological malignancies.

Authors:  E Rintala; K Irjala; J Nikoskelainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

6.  Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients.

Authors:  Junyan Qu; Xiaoju L; Yanbin Liu; Xiaohui Wang
Journal:  Indian J Med Res       Date:  2015-03       Impact factor: 2.375

7.  Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial.

Authors:  Serge Masson; Pietro Caironi; Eberhard Spanuth; Ralf Thomae; Mauro Panigada; Gabriela Sangiorgi; Roberto Fumagalli; Tommaso Mauri; Stefano Isgrò; Caterina Fanizza; Marilena Romero; Gianni Tognoni; Roberto Latini; Luciano Gattinoni
Journal:  Crit Care       Date:  2014-01-07       Impact factor: 9.097

Review 8.  Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.

Authors:  Paola Villafuerte-Gutierrez; Lucia Villalon; Juan E Losa; Cesar Henriquez-Camacho
Journal:  Adv Hematol       Date:  2014-11-27

9.  Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients.

Authors:  Yusuke Koizumi; Kaoru Shimizu; Masayo Shigeta; Takafumi Okuno; Hitoshi Minamiguchi; Katsuyuki Kito; Keiko Hodohara; Yuka Yamagishi; Akira Andoh; Yoshihide Fujiyama; Hiroshige Mikamo
Journal:  BMC Infect Dis       Date:  2017-01-05       Impact factor: 3.090

10.  Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients.

Authors:  Kuntegowdanahalli C Lakshmaiah; Abhayakumar S Malabagi; Rachan Shetty; Mahua Sinha; Rudrapatna S Jayashree
Journal:  J Lab Physicians       Date:  2015 Jul-Dec
View more
  6 in total

1.  Febrile illness in high-risk children: a prospective, international observational study.

Authors:  Fabian J S van der Velden; Gabriella de Vries; Alexander Martin; Emma Lim; Ulrich von Both; Laura Kolberg; Enitan D Carrol; Aakash Khanijau; Jethro A Herberg; Tisham De; Rachel Galassini; Taco W Kuijpers; Federico Martinón-Torres; Irene Rivero-Calle; Clementien L Vermont; Nienke N Hagedoorn; Marko Pokorn; Andrew J Pollard; Luregn J Schlapbach; Maria Tsolia; Irini Elefhteriou; Shunmay Yeung; Dace Zavadska; Colin Fink; Marie Voice; Werner Zenz; Benno Kohlmaier; Philipp K A Agyeman; Effua Usuf; Fatou Secka; Ronald de Groot; Michael Levin; Michiel van der Flier; Marieke Emonts
Journal:  Eur J Pediatr       Date:  2022-10-15       Impact factor: 3.860

2.  Can presepsin uniformly respond to various pathogens? - an in vitro assay of new sepsis marker.

Authors:  Yusuke Koizumi; Daisuke Sakanashi; Tetsuo Mohri; Hiroki Watanabe; Arufumi Shiota; Nobuhiro Asai; Hideo Kato; Mao Hagihara; Kenta Murotani; Yuka Yamagishi; Hiroyuki Suematsu; Hiroshige Mikamo
Journal:  BMC Immunol       Date:  2020-06-05       Impact factor: 3.615

3.  The Association between Dynamic Changes in Serum Presepsin Levels and Mortality in Immunocompromised Patients with Sepsis: A Prospective Cohort Study.

Authors:  Jongmin Lee; Seohyun Kim; Kyung Hoon Kim; Na Ri Jeong; Seok Chan Kim; Eun-Jee Oh
Journal:  Diagnostics (Basel)       Date:  2021-01-02

4.  Biomarkers for Diagnosing Febrile Illness in Immunocompromised Children: A Systematic Review of the Literature.

Authors:  Fabian J S van der Velden; Andrew R Gennery; Marieke Emonts
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

5.  Is There a Role of Presepsin as a Novel Biomarker in Pediatric Sepsis?

Authors:  Daisy Khera; Nisha Toteja; Surjit Singh; Simranjeet Singh; Prawin Kumar; Praveen Sharma; Kuldeep Singh
Journal:  Indian J Crit Care Med       Date:  2022-06

6.  Performance of presepsin and procalcitonin predicting culture-proven bacterial infection and 28-day mortality: A cross sectional study.

Authors:  Jiho Park; Ji Hyun Yoon; Hyun Kyun Ki; Jae-Hoon Ko; Hee-Won Moon
Journal:  Front Med (Lausanne)       Date:  2022-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.